MORRISTOWN, NJ (March 18, 2019). BioAegis Therapeutics Inc. announced that it has completed patient enrollment in its Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) as adjunctive therapy for patients requiring hospitalization because of Community-Acquired Pneumonia (CAP).
A Novel Approach to Create a New Treatment Paradigm
Severe CAP is the lead indication of this clinical-stage company that addresses infectious, inflammatory and degenerative diseases with supplementation of an endogenous protein that is depressed in these disorders.
Patients were treated with recombinant human plasma gelsolin (rhu-pGSN) or a matching placebo in this blinded randomized clinical trial.

Read the full press release here: 2019 03 18 Completes Enrollment Phase 1b_2a

MORRISTOWN, NJ, (BIOAEGIS THERAPEUTICS) March 13, 2019 BioAegis Therapeutics Inc., a privately held biotechnology company commercializing plasma gelsolin (pGSN), an endogenous human protein that harnesses the innate immune system to modulate the inflammatory response as well as boost the capacity of immune cells to fight infection announced today that the European Patent Office has issued a patent for the Use of Plasma Gelsolin to Treat Infections.  This grant adds to BioAegis’ infection portfolio already covered by patents in the US, China and other territories.

Read the full press release here: European Infection Patent

MORRISTOWN, N.J., Feb. 07, 2019 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc. announced that patient enrollment is underway in a Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) in Community-Acquired Pneumonia (CAP) in the Republic of Georgia. The clinical-stage company is focused on a novel approach to address infectious, inflammatory and degenerative diseases through a portfolio built around the supplementation of plasma gelsolin levels. The Data Safety Monitoring Board (DSMB) met on 25 Jan 2019 to review the safety data for the 6 mg/kg multiple dose level (cohort 2). Review of the safety data did not reveal any safety concerns and accordingly the DSMB recommended to start enrollment into the 12 mg/kg multiple ascending dose level (cohort 3).

Read the full press release here: BioAegis Expands Phase 1b_2a Community-Acquired Pneumonia Study to the Republic of Georgia

MORRISTOWN, N.J., Feb. 01, 2019 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc. announced the publication of a paper in Clinical Infectious Disease—a journal of the Infectious Disease Society of America entitled, Low Admission Plasma Gelsolin Concentrations Identify Community-acquired Pneumonia (CAP) Patients at High Risk for Severe Outcomes.  BioAegis, together with Investigators at Vanderbilt and Northwestern Universities as well as the CDC, retrospectively analyzed samples from the previously completed CDC-Sponsored EPIC study that prospectively followed several thousand CAP patients.

Read the full press release here: Publication in “Clinical Infectious Diseases”

New Patents Issued Across Multiple Geographies in US, China, Hong Kong and Australia

BOSTON, MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – December, 2017) BioAegis Therapeutics announces that during 2018 its patent portfolio expanded globally in multiple indications. The newly issued patents extend coverage in infection, inflammatory disease, and neurological disease in the United States, China, Honk Kong and Australia. The plasma gelsolin portfolio now includes 30 issued patents and many pending applications.